OraSure Technologies, Inc. OSUR

Company Overview

OraSure Technologies, Inc. is a U.S.-based diagnostics and life sciences company focused on point-of-care testing, molecular specimen collection, and microbiome and genomic services. The company operates primarily in the in vitro diagnostics and life sciences tools industries, with products and services used by healthcare providers, laboratories, public health organizations, research institutions, and commercial customers. OraSure is widely known for its oral fluid diagnostic technologies, including rapid infectious disease testing and specimen collection systems designed for decentralized and non-invasive testing environments.

The company’s principal revenue drivers include its Diagnostics business and its Sample Management Solutions business. Key products include oral fluid HIV tests, specimen collection devices for molecular diagnostics, and microbiome collection and stabilization products. OraSure has historically differentiated itself through proprietary oral fluid technologies, established regulatory clearances, and relationships with public health agencies and laboratory customers. Founded in 1987 and headquartered in Bethlehem, Pennsylvania, the company expanded from infectious disease diagnostics into genomics, microbiome services, and molecular sample management through internal development and acquisitions.

Business Operations

OraSure organizes operations primarily through its Diagnostics and Sample Management Solutions segments. The Diagnostics segment includes rapid tests for infectious diseases and other health conditions, including products used in HIV screening and decentralized testing settings. The Sample Management Solutions segment includes specimen collection, stabilization, and transport products used in molecular diagnostics, genomics, and microbiome research. Revenue is generated through direct product sales, laboratory-related services, and commercial partnerships with healthcare organizations, laboratories, and research institutions.

The company operates across domestic and international markets, with sales channels in North America, Europe, Asia-Pacific, Latin America, and parts of Africa. OraSure controls proprietary oral fluid collection technologies and intellectual property associated with sample stabilization and transport. Major subsidiaries and operating brands include DNA Genotek, which specializes in genomic and microbiome sample collection technologies. OraSure has also collaborated with public health agencies, diagnostic distributors, and research organizations to support infectious disease screening and molecular testing initiatives.

Strategic Position & Investments

OraSure’s strategic direction has centered on expanding its molecular collection and decentralized diagnostics capabilities while reducing reliance on any single testing category. The company has invested in molecular specimen collection technologies, microbiome research tools, and scalable diagnostic platforms designed for laboratory and at-home use cases. Management has also focused on strengthening recurring revenue streams tied to research, genomics, and biopharmaceutical customers.

The acquisition of DNA Genotek significantly expanded OraSure’s presence in genomics and microbiome applications, adding saliva-based DNA and RNA collection technologies used in research and clinical settings. OraSure has also pursued investments tied to infectious disease preparedness, decentralized healthcare delivery, and molecular diagnostics infrastructure. Its strategic positioning benefits from established regulatory expertise, specialized oral fluid technologies, and long-standing relationships with healthcare and laboratory customers, though portions of its recent operating performance have been influenced by fluctuations in COVID-19-related testing demand.

Geographic Footprint

OraSure Technologies is headquartered in Bethlehem, Pennsylvania, and maintains operations, distribution networks, and customer relationships across multiple global regions. Its products are marketed throughout North America, Europe, Asia-Pacific, Latin America, and selected markets in Africa and the Middle East. The company’s international reach is supported by direct commercial operations as well as distributor and laboratory partnerships.

The company’s global footprint has been strengthened through DNA Genotek, which operates from Canada and supports customers in genomic research, clinical testing, and microbiome analysis worldwide. OraSure’s technologies are used by government health agencies, hospitals, laboratories, universities, and commercial life sciences organizations across both developed and emerging markets.

Leadership & Governance

OraSure Technologies operates under a corporate governance structure led by a board of directors and executive leadership team with experience across diagnostics, healthcare, medical technology, and life sciences. Leadership has emphasized operational efficiency, product diversification, innovation in sample collection technologies, and expansion into higher-growth molecular and genomic markets.

Key executives include:

• Carrie Eglinton Manner – President and Chief Executive Officer
• Kenneth “Danny” Fang – Chief Financial Officer
• Michael L. Little – Executive Vice President, International Business
• Kathleen Weber – Executive Vice President and General Manager, Molecular Solutions
• Brian Smith – Executive Vice President, Human Resources

The company’s leadership philosophy has focused on leveraging proprietary technologies, expanding decentralized diagnostic access, and supporting long-term growth through innovation in molecular and oral fluid-based testing solutions.